Neuromyelitis spektrum betegség új nemzetközi ajánlás, új terápiás lehetőségek; hol tart a hazai gyakorlat diagnosztikában és terápiás lépésekben? [Neuromyelitis optica spectrum disorder: new international recommendations and emerging therapeutic options; current status of domestic practice in diagnostics and therapeutic strategies] /

Neuromyelitis optica spectrum disorder is a rare neuroimmunological disease associated with unpredictable deterioration. Even the first signs of the disease can be severe enough to lead to permanent neurological impairment, such as loss of vision or paralysis. Early symptoms can often be mistaken fo...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerző: Rajda Cecília
Dokumentumtípus: Cikk
Megjelent: 2025
Sorozat:IDEGGYOGYASZATI SZEMLE / CLINICAL NEUROSCIENCE 78 No. 9-10
Tárgyszavak:
doi:10.18071/isz.78.0295

mtmt:36383504
Online Access:http://publicatio.bibl.u-szeged.hu/39362
LEADER 01906nab a2200217 i 4500
001 publ39362
005 20260224114452.0
008 260224s2025 hu o 000 hun d
022 |a 0019-1442 
024 7 |a 10.18071/isz.78.0295  |2 doi 
024 7 |a 36383504  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a hun 
100 1 |a Rajda Cecília 
245 1 0 |a Neuromyelitis spektrum betegség  |h [elektronikus dokumentum] :  |b új nemzetközi ajánlás, új terápiás lehetőségek; hol tart a hazai gyakorlat diagnosztikában és terápiás lépésekben? [Neuromyelitis optica spectrum disorder: new international recommendations and emerging therapeutic options; current status of domestic practice in diagnostics and therapeutic strategies] /  |c  Rajda Cecília 
260 |c 2025 
300 |a 295-305 
490 0 |a IDEGGYOGYASZATI SZEMLE / CLINICAL NEUROSCIENCE  |v 78 No. 9-10 
520 3 |a Neuromyelitis optica spectrum disorder is a rare neuroimmunological disease associated with unpredictable deterioration. Even the first signs of the disease can be severe enough to lead to permanent neurological impairment, such as loss of vision or paralysis. Early symptoms can often be mistaken for another disease, leaving patients bouncing between several specialists, leading to diagnostic delay. Early detection of the disease can save lives and quality of life, as appropriate therapy started early can prevent neurologically debilitating deterioration. In Hungary, the "off label" rituximab has so far been given a facilitated procedure for therapy, while evidence-based medicines are not yet available to us. 
650 4 |a Klinikai orvostan 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/39362/1/neuromyelitis-optica-spectrum-disorder-new-international-recommendations-and-emerging-therapeutic-options-current-status-of-domestic-practice-in-diagnostics-and-therapeutic-strategies.pdf  |z Dokumentum-elérés